• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Allscripts Swallows Poison Pill to Avoid Hostile Takeover

by Fred Pennic 05/07/2012 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

poison-pill Allscripts Healthcare Solutions, Inc. announced on Monday adopted a shareholder rights plan, also commonly called a “poison pill” to protect itself from any potential hostile takeover approaches in the wake of firing the chairman and departure of three board members that sent its stock price tumbling 34% since April 26. The New York Hedge Fund that holds 4.9% of the company along with other large shareholders demanded the resignation of CEO Glen Tullman citing  weak forecast reporting a 54% decline in first quarter profits and issues with the execution of integrating Eclipsys Corp, the software vendor that it bought two years ago for $1.3 billion in stock.

Under the shareholder rights plan, stockholders will receive rights to purchase shares of a new series of preferred stock in certain circumstances. The rights will be exercisable if a person or group, without board approval, acquires 10% or more of Allscripts’ common stock. The plan exempts any person or group already owning 10% or more of Allscripts’ shares, but it may be exercisable if they acquire any additional shares. The plan will expire May 6, 2013.

In a Monday statement, newly named Chairman Dennis Chookaszian said the board believes that the current share price does not reflect the company’s long-term potential. Chookaszian said the anti-takeover measure was “a temporary measure that is consistent with the board’s fiduciary duties.”

 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Allscripts

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

 Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Samsung Acquires Xealth to Accelerate Connected Care Vision

Samsung Acquires Xealth to Accelerate Connected Care Vision

AI Dominates Digital Health Investment in First Half of 2025

Rock Health Report: AI Dominates Digital Health Investment in First Half of 2025

Moving Beyond EHRs: What Lies Ahead for Healthcare Digitization?

AI Agents vs. Chatbots: Understanding Agentic AI’s Role in Healthcare

AI Breakthrough Reveals 2025 AI Breakthrough Award Winners

AI Breakthrough Reveals 2025 AI Breakthrough Award Winners

Healthcare's Big Blind Spot: The Measurement Crisis in Inpatient Psychiatry

Healthcare’s Big Blind Spot: The Measurement Crisis in Inpatient Psychiatry

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |